Trials / Completed
CompletedNCT00524537
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,025 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Registry study is to evaluate the long-term safety and effectiveness of adalimumab in CD subjects who are treated as recommended in the product label.
Conditions
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2007-09-03
- Last updated
- 2017-01-24
- Results posted
- 2017-01-24
Source: ClinicalTrials.gov record NCT00524537. Inclusion in this directory is not an endorsement.